Mounjaro®
Starting from £179.99/mo
Start journey Learn moreGenerally, yes: the clinical trial data show that higher doses of Mounjaro (tirzepatide) produce greater average weight loss. In SURMOUNT-1, adults on the 15mg maintenance dose lost around 20–21% of body weight on average over 72 weeks, compared with roughly 15% at the 5mg dose — a meaningful difference. That said, the right dose for any individual is a clinical decision, not a simple case of more always being better. Mounjaro is a prescription-only medicine, and a GPhC-registered prescriber determines which dose is appropriate based on your response, how well you're tolerating each step, and your overall health picture.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The SURMOUNT-1 trial, published in the New England Journal of Medicine, is the clearest source of evidence here. Over 72 weeks, adults with obesity who had no diabetes lost an average of around 15% of body weight on the 5mg dose, roughly 19.5% on 10mg, and approximately 20–21% on 15mg. The differences are real and statistically significant. The pattern is consistent: each step up in dose tends to deliver more weight loss at a group level, though whether a higher dose of Mounjaro will mean more weight loss for you personally is a more nuanced question than the averages alone suggest.
But group averages hide important individual variation. Some participants on 10mg lost more than the group average at 15mg. Others on a lower dose reached a stable, healthy weight that met their personal goals without ever needing the maximum. The trial enrolled thousands of adults, which gives the results statistical power, but it cannot predict your personal trajectory. That uncertainty is exactly why clinical assessment matters at every stage of treatment.
For a fuller breakdown of how dose and outcomes are related across the full Mounjaro range, the evidence behind higher doses and weight loss is worth reading alongside this page.
Mounjaro's titration schedule exists for a reason. Treatment begins at 2.5mg, a dose designed to let your digestive system adjust gradually. Nausea, bloating and appetite changes are most pronounced in the first few weeks at a new dose level; moving up before those effects settle tends to compound them. The licensed schedule typically increases the dose every four weeks, though this can be slower depending on tolerance.
The decision your prescriber is weighing at each step is: is the additional weight-loss potential of a higher dose likely to outweigh the increased side-effect burden for this particular person? For many people, the answer at 5mg or 7.5mg is yes, progress is meaningful but there is still room to improve. For others, especially those who have already reached a weight that no longer poses a health risk, the calculus shifts.
There is also a practical timing consideration. If you are due for a dose review at an inconvenient moment (around a holiday, or a week when you know you will be eating differently) your prescriber may advise holding your current dose for a further four weeks rather than increasing it. The schedule is a guide, not a rigid contract.
If you are thinking about what weight loss to expect at the 5mg level specifically, the 5mg results page sets out the evidence in more detail.
There is a point, different for every person, where additional dose increases yield smaller returns. This is not a failure of the medicine, it reflects the biology of weight regulation. Once the body reaches a new equilibrium, appetite-suppression signals from tirzepatide are already doing substantial work, and the incremental gain from moving from, say, 10mg to 12.5mg may be modest for some people while the side-effect profile becomes more pronounced.
NICE's appraisal of tirzepatide (TA1026) notes that treatment should be reviewed if less than 5% of body weight is lost after six months at the highest tolerated dose. That threshold reflects real-world clinical practice: if the medicine is not working sufficiently at a dose you can tolerate, continuing to push upward is not necessarily the answer. Your prescriber may consider whether lifestyle factors, medication interactions, or another approach should be part of the conversation.
Understanding how Mounjaro higher doses work in practice can help you go into that review with the right questions. The key point is that the goal is the dose that works best for you, which is a clinical judgement, not a number you should feel pressure to reach.
The practical upshot is straightforward. If you are early in treatment, on 2.5mg or 5mg, and wondering whether you need a higher dose to see results, the honest answer is: give each dose level time. Weight loss at 2.5mg is typically modest, because that dose was not designed for maximum effect. Many people notice more meaningful progress from 5mg onwards, and again from 7.5mg. Appetite tends to reduce noticeably with each increase.
If you are considering starting Mounjaro and wondering what to expect at different stages, the Mounjaro overview covers the full picture, from how it works to what the treatment process looks like in practice. And if cost across the dose range is part of your thinking, the Mounjaro pricing page sets out what private treatment typically involves.
At nume, every repeat prescription involves a clinical review before anything is dispensed. A real prescriber looks at your progress, your current dose and your reported experience at each stage. If a dose increase makes clinical sense, we can progress it; if staying put is the right call, we will tell you that too. Check your eligibility and speak to our prescribers through a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.